UNSPSC 51461603: Chondroitin/glucosamine/hyaluronate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HA000. This VA Drug Class (HA000) classifies this compound as belonging to the group HERBS/ALTERNATIVE THERAPIES.

UNSPSC 51461603 Chondroitin/glucosamine/hyaluronate is a Commodity code encompassing over-the-counter joint health and nutritional supplement products supplied to state and local government facilities. State and local procurement under this code focuses on generic multi-source pharmaceuticals and OTC products distributed through authorized pharmaceutical wholesalers to support healthcare and wellness programs across participating agencies. The buying profile emphasizes cost-effective, FDA-compliant formulations with established National Drug Codes and standardized packaging for inventory management across multiple facilities. Issuing bodies include state departments of administration, cooperative purchasing alliances spanning multiple states and jurisdictions, and member government agencies relying on centralized procurement contracts to standardize product availability and pricing.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products including chondroitin/glucosamine/hyaluronate formulations, with proposals due March 26, 2026 and contract performance commencing July 1, 2026. The solicitation covers Minnesota, Oregon, and other MMCAP member jurisdictions, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and demonstrating pricing flexibility across fixed-price, net-price, and WAC-minus formats. Evaluation weights pricing competitiveness at 75 percent, with administrative compliance, EDI capability, and pricing-format compliance comprising the remainder, and successful vendors must maintain comprehensive insurance coverage including $5,000,000 commercial general liability and satisfy cGMP and Drug Supply Chain Security Act compliance. Contract terms span two years for new vendors with optional extensions, subject to performance penalties of $200 to $1,500 per violation for reporting delays, onboarding failures, or improper class-of-trade denials.